Biodexa Pharmaceuticals (BDRX) AI Stock Analysis

• Market Cap: $3.97M
• Dividend Yield: N/A
• Average Volume (3M): 42.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: -100.00%
• EPS Growth: 86.75%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 619,523
• 10 Day Avg. Volume: 30,445
• 30 Day Avg. Volume: 42,356
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.67
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.82
• Enterprise Value/Ebitda: 0.33
• 1Y Price Target: $18.00
• Price Target Upside: 183.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.

Biodexa Pharmaceuticals Business Overview & Revenue Model

Company Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

How the Company Makes Money

Biodexa Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products and drug delivery technologies. The company's revenue model is primarily based on sales of its proprietary drug formulations and delivery systems to healthcare providers, pharmaceutical companies, and distributors. Additionally, Biodexa may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to further develop and market its technologies, which can provide additional revenue streams through milestone payments, royalties, or co-development deals. Key factors contributing to its earnings include successful clinical trials, regulatory approvals, and the ability to effectively market its products to target demographics.

Biodexa Pharmaceuticals Financial Statement Overview

Summary

Biodexa Pharmaceuticals demonstrates weak financial performance with declining revenues, negative profitability margins, and persistent cash flow issues. Despite a favorable debt-to-equity ratio, the overall financial health is compromised by ongoing losses and inefficiencies in generating profits.

Income Statement

Biodexa Pharmaceuticals shows a decreasing revenue trend over the years with a significant decline from $674,000 in 2019 to $381,000 in 2023. The gross profit margin is negative, indicating cost of goods sold surpasses revenue. Net profit margin is also negative, representing ongoing unprofitability. Despite some improvement in EBITDA margin, overall financial health remains weak due to persistent losses.

Balance Sheet

The debt-to-equity ratio is favorable, with relatively low leverage indicating the company relies more on equity than debt for financing. The equity ratio is stable, reflecting moderate financial stability. However, consistent negative net income impacts the return on equity, suggesting inefficiencies in generating profits from shareholders' equity.

Cash Flow

Operating cash flow remains negative, signaling challenges in generating cash from operations. Free cash flow shows a slight improvement but remains negative, indicating ongoing cash burn. The operating cash flow to net income ratio suggests that cash generation issues are consistent with net losses. Financing activities are primarily funding operations, as seen from significant cash inflows.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	381.00K	699.00K	578.00K	343.00K
Gross Profit	-5.44M	-3.69M	-4.41M	-4.08M	-5.72M
EBITDA	-9.08M	-7.16M	-7.39M	-5.66M	-22.22M
Net Income	-5.73M	-7.08M	-7.66M	-5.46M	-22.19M
Balance Sheet
Total Assets	14.78M	10.54M	5.53M	12.91M	9.82M
Cash, Cash Equivalents and Short-Term Investments	1.67M	5.97M	2.84M	10.06M	7.55M
Total Debt	727.00K	464.00K	624.00K	766.00K	260.00K
Total Liabilities	6.46M	5.86M	2.36M	2.46M	3.10M
Stockholders Equity	8.32M	4.68M	3.16M	10.45M	6.72M
Cash Flow
Free Cash Flow	-13.04M	-7.09M	-7.11M	-6.33M	-9.51M
Operating Cash Flow	-12.26M	-6.83M	-7.05M	-6.01M	-9.30M
Investing Cash Flow	-598.00K	-265.00K	-220.00K	-278.00K	2.57M
Financing Cash Flow	8.56M	10.23M	47.00K	8.80M	3.08M

Biodexa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Positive. The current price of 6.35 is above the 20-day moving average (MA) of 6.01, below the 50-day MA of 6.85, and below the 200-day MA of 20.29, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 53.71 is Neutral, neither overbought nor oversold. The STOCH value of 51.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDRX.

Biodexa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XOMA	61 Neutral	444.59M	-23.15	-16.87%	―	194.98%	38.01%
FRX	58 Neutral	323.96M	-20.51	―	―	-29.70%	-546.01%
MRNS	48 Neutral	29.96M	-0.22	210.50%	―	1.63%	6.97%
BDRX	45 Neutral	$3.97M	―	-60.37%	―	-100.00%	86.75%
AKTX	44 Neutral	36.20M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%